alendronate has been researched along with Invasiveness, Neoplasm in 9 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our findings suggest that alendronate may reduce MMP-2 secretion at the transcriptional and translational levels, and inhibit the invasion of chondrosarcoma cell." | 7.74 | Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. ( Chou, MC; Fong, YC; Hsu, CJ; Hsu, HC; Hsu, SF; Lai, TJ; Lee, MC; Li, TM; Lin, JG; Yang, SF, 2007) |
| "Two osteosarcoma cell lines (SaOS-2, U(2)OS) were treated with alendronate (50, 100, and 150 microM) for 24 and 48 hr." | 7.72 | Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. ( Cheng, YY; Huang, L; Kumta, SM; Lee, KM; Li, K, 2004) |
| "Our findings suggest that alendronate may reduce MMP-2 secretion at the transcriptional and translational levels, and inhibit the invasion of chondrosarcoma cell." | 3.74 | Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. ( Chou, MC; Fong, YC; Hsu, CJ; Hsu, HC; Hsu, SF; Lai, TJ; Lee, MC; Li, TM; Lin, JG; Yang, SF, 2007) |
| "Two osteosarcoma cell lines (SaOS-2, U(2)OS) were treated with alendronate (50, 100, and 150 microM) for 24 and 48 hr." | 3.72 | Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. ( Cheng, YY; Huang, L; Kumta, SM; Lee, KM; Li, K, 2004) |
| "Metastatic prostate cancer is associated with a high morbidity and mortality but the spreading mechanisms are still poorly understood." | 1.35 | Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. ( Härkönen, PL; Tuomela, JM; Väänänen, K; Valta, MP, 2008) |
| "We established an in vivo ovarian cancer model with i." | 1.33 | Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. ( Hashimoto, K; Ikebuchi, Y; Kawagishi, R; Morishige, K; Murata, Y; Sakata, M; Sawada, K; Tahara, M; Tasaka, K, 2005) |
| "Alendronate pretreatment also inhibited migration, which was partially reversed by geranylgeraniol and trans-trans-farnesol." | 1.31 | Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. ( Härkönen, PL; Lakkakorpi, PT; Väänänen, HK; Virtanen, SS, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshitani, K | 1 |
| Kido, A | 1 |
| Honoki, K | 1 |
| Akahane, M | 1 |
| Fujii, H | 1 |
| Tanaka, Y | 1 |
| Cheng, YY | 1 |
| Huang, L | 1 |
| Lee, KM | 1 |
| Li, K | 1 |
| Kumta, SM | 1 |
| Andela, VB | 1 |
| Hashimoto, K | 1 |
| Morishige, K | 1 |
| Sawada, K | 1 |
| Tahara, M | 1 |
| Kawagishi, R | 1 |
| Ikebuchi, Y | 1 |
| Sakata, M | 1 |
| Tasaka, K | 1 |
| Murata, Y | 1 |
| Lai, TJ | 1 |
| Hsu, SF | 1 |
| Li, TM | 1 |
| Hsu, HC | 1 |
| Lin, JG | 1 |
| Hsu, CJ | 1 |
| Chou, MC | 1 |
| Lee, MC | 1 |
| Yang, SF | 1 |
| Fong, YC | 1 |
| Tuomela, JM | 1 |
| Valta, MP | 1 |
| Väänänen, K | 1 |
| Härkönen, PL | 2 |
| Adami, S | 1 |
| Teronen, O | 1 |
| Heikkilä, P | 1 |
| Konttinen, YT | 1 |
| Laitinen, M | 1 |
| Salo, T | 1 |
| Hanemaaijer, R | 1 |
| Teronen, A | 1 |
| Maisi, P | 1 |
| Sorsa, T | 1 |
| Virtanen, SS | 1 |
| Väänänen, HK | 1 |
| Lakkakorpi, PT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alendronate and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Bisphosphonates in prostate carcinoma.
Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; C | 1997 |
8 other studies available for alendronate and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Low concentrations of alendronate increase the local invasive potential of osteoblastic sarcoma cell lines via connexin 43 activation.
Topics: Alendronate; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; C | 2011 |
Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines.
Topics: Alendronate; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Dose-Response Relationship, Drug; | 2004 |
Correspondence Re S. S. Virtanen et al., Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002;62:2708-14. Re K. Sawada et al., Alendronate inhibits lysophosphatidic acid-induced migration of huma
Topics: Alendronate; Humans; Male; Mevalonic Acid; Neoplasm Invasiveness; Prostatic Neoplasms | 2004 |
Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.
Topics: Alendronate; Animals; CA-125 Antigen; Cell Line, Tumor; Disease Progression; Female; Mice; Mice, Inb | 2005 |
Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line.
Topics: Alendronate; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Chondrosarcoma; Humans; | 2007 |
Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice.
Topics: Adenocarcinoma; Alendronate; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Divi | 2008 |
MMP inhibition and downregulation by bisphosphonates.
Topics: Alendronate; Antineoplastic Agents; Body Fluids; Collagenases; Diphosphonates; Gene Expression Regul | 1999 |
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Topics: Alendronate; Antimetabolites; Bone Neoplasms; Cell Movement; Clodronic Acid; Dose-Response Relations | 2002 |